Pembrolizumab

BNF:
8.1.5
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

RED:

  • NICE TA357: for treating advanced melanoma after disease progression with ipilimumab (Decision date - November 2015)
  • NICE TA366: for treating advanced melanoma not previously treated with ipilimumab (Decision date - December 2015)
  • NICE TA428: for treating PDL1-positive non-small-cell lung cancer after chemotherapy (Decision date - February 2017)
  • NICE TA519: for the treatment of locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (Decision date - May 2018)
  • NICE TA531: for untreated PD-L1 positive metastatic non-small-cell lung cancer (Replaces TA447) (Decision date - August 2018)
  • NICE TA553: for adjuvant treatment of resected melanoma with high risk of reoccurrence (Decision date - January 2019)
  • NICE TA600: with carboplatin and paclitaxel for untreated metastatic squamous NSCLC. (Decision date - October 2019)
  • NICE TA650: with axitinib for untreated advanced renal cell carcinoma. (Decision date - October 2020)
  • NICE TA661: for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. (Decision date - December 2020)
  • NICE TA683with pemetrexed and platinum chemotherapy for untreated metastatic, non-squamous non-small-cell lung cancer (Replaces TA557) (Decision date - April 2021)
  • NICE TA709: for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (Decision date - July 2021)
  • NICE TA737: with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer. (Decision date - Nov 2021)
  • NICE TA766: for adjuvant treatment of completely resected stage 3 melanoma. (Decision date - March 2022)
  • NICE TA770: with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer. (Decision date - March 2022)
  • NICE TA772: for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies. (Decision date - March 2022)
  • NICE TA801 - Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. NHSE commissioned. (Decision date - July 2022)
  • NICE TA830 - Pembrolizumab for adjuvant treatment of renal cell carcinoma. (Decision date - November 2022)
  • NICE TA837 - Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma. NHSE commissioned. (Decision date - November 2022) 
  • NICE TA851 - Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. (Decision date - January 2023)
  • NICE TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer. (Decision date - July 2023)
  • NICE TA914 -  Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (Decision date - October 2023)
  • NICE TA939Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (replaces NICE TA885) NHSE commissioned.

DO NOT PRESCRIBE (DNP):

  • NICE TA540: for treating relapsed or refractory classical Hodgkin lymphoma (Decision date - October 2018)
  • NICE TA570: for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (Decision date - April 2019)
  • NICE TA674: for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (Replaces TA522) (Decision date - March 2021)
  • NICE TA692: for treating locally advanced or metastatic urothelial carcinoma after platinum containing chemotherapy (Decision date - May 2021)


Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app